Green Heart Growth Search Results

    Events (1)View All
    Pages (16)
    • Certification of Analysis | Green Heart Growth Hemp Derived Products

      Green Heart Growth Certificate of Analysis (COA) are Tested by our and Shipped Directly to us. Upon receipt, we send our own samples to a 3rd Party Lab, , for additional Analytical. Green Heart Growth's Products Vertically Integrated Supplier Proverde Labs

    • Testimonials | Green Heart Growth Hemp-Derived Products

      Customer Testimonials and Reviews We're currently experiencing difficulties displaying our reviews. Below are images for the time being. Thanks!

    • Clinical CBD Studies | Green Heart Growth Hemp Derived Products

      Green Heart Growth CBD Clinical Studies and Publications Looking for more Cannabis Information? is an excellent resource for CBD & THC research, clinical trials and more. Pubmed.gov NCBI | US National Library of Medicine | National Institutes of Health Below is the cited reference list from Sean M. Westmeier's Cannabidiol (CBD) Review - Potential Benefits Relating to Functional, Healthy Balance If you're looking for more information on Cannabidiol (CBD) and Potential Therapeutic Benefits Relating to Issues with Sleep, Anxiety, Headaches, Migraines, Hangovers, Arthritis, Allergies we Highly Recommend checking the Source of the Cited Articles. Go to the Source and Learn More. We all are! www.pubmed.gov Bih, C.I., et al., Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 2015. 12(4): p. 699-730. https://www.ncbi.nlm.nih.gov/pubmed/26264914 Machado Bergamaschi, M., et al., Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent. https://www.ncbi.nlm.nih.gov/pubmed/22129319 Current Drug Safety, 2011. 6(4): p. 237-249. ​ Marks, M.D., et al., Identification of candidate genes affecting Δ(9)- tetrahydrocannabinol biosynthesis in Cannabis sativa. Journal of Experimental Botany, 2009. 60(13): p. 3715-3726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736886/ ​ Jiang, R., et al., Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci, 2011. 89(5-6): p. 165-70. https://www.ncbi.nlm.nih.gov/pubmed/21704641 ​ Cunetti, L., et al., Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc, 2018. 50(2): p. 461-464 https://www.ncbi.nlm.nih.gov/pubmed/29579828 ​ Hundal, H., et al., The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol, 2018. 32(3): p. 276-282. https://www.ncbi.nlm.nih.gov/pubmed/29086614 ​ Pisanti, S., et al., Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther, 2017. 175: p. 133-150 https://www.ncbi.nlm.nih.gov/pubmed/28232276 ​ Devinsky, O., et al., Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014. 55(6): p. 791-802 https://www.ncbi.nlm.nih.gov/pubmed/24854329 ​ Irving, P.M., et al., A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis, 2018. 24(4): p.714-724 https://www.ncbi.nlm.nih.gov/pubmed/29538683 ​ https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf ​ June 26th, 2018 - FDA Approved Epidiolex - Created and Sold by GW Pharmaceutical https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms ​ Fasinu, P.S., et al., Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy, 2016. 36(7): p. 781-796 https://www.ncbi.nlm.nih.gov/pubmed/27285147 ​ Iffland, K. and F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2017. 2(1): p. 139-154 https://www.ncbi.nlm.nih.gov/pubmed/28861514 ​ Pertwee, R., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐ tetrahydrocannabivarin. British journal of pharmacology, 2008. 153(2): p. 199-215 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219532/ ​ McPartland, J.M., et al., Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 2015. 172(3): p. 737-753 https://www.ncbi.nlm.nih.gov/pubmed/25257544

    View All
    Forum Posts (4)View All